CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.
about
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseasesInducing and Administering Tregs to Treat Human DiseaseBiologics in dermatologic therapy - an update.T cells in the control of organ-specific autoimmunityBiological therapies in the systemic management of psoriasis: International Consensus Conference.Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.Alefacept: a review of the literature and practical guidelines for management.Alefacept is well tolerated in patients with chronic plaque psoriasis.Psoriasis: emerging therapeutic strategies.Alefacept for psoriasis and psoriatic arthritis.Alefacept: a safety profile.The vertebral artery: a review of anatomical, histopathological and functional factors influencing blood flow to the hindbrain.Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis.Biologic agents in psoriasis.The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis.Immunobiologics in the treatment of psoriasis.Biologic therapeutics in the treatment of psoriasis. Part 1: review.Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.Alefacept for the treatment of psoriasis and other dermatologic diseases.National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.Update on the natural history and systemic treatment of psoriasis.From conventional to cutting edge: the new era of biologics in treatment of psoriasis.Infectious complications associated with monoclonal antibodies and related small moleculesBiological agents targeting beyond TNF-alpha.Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.Novel immunobiologics for psoriasis.Preface: real-world clinical experience with alefacept-the Amevive Wisdom Acquired from Real-World Evidence (AWARE) study.Alefacept: where it stands today.Immunotargeting in the management of psoriasis.Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
P2860
Q24646861-BAA8FBFF-4B8C-4B3F-A459-2D52C1F9B54CQ24676659-5509CDDC-DEF9-476D-B209-9ACEA0B5D8ADQ26772723-507DACFE-FB3F-4440-A21C-47FC8362466EQ33607620-72BB2E26-CEB8-4D5F-B52B-A8047A606885Q35836118-15BF512F-47CE-4E54-AFFD-23FAC540F2B0Q35841615-7C8EC93C-1393-428F-8F8A-7FD8B7D124EFQ35868862-2CFECD84-17B0-4927-B841-5301884D4B3DQ35893152-4C234FFC-9650-4B02-A991-CE38D870F904Q36019379-ABEA4B51-C2F0-45F7-A0B2-3E66D2BDE8ABQ36028220-05C78323-6578-438A-9A9C-6BCB81FED46EQ36292648-AAF992C5-A323-4E0A-BA83-A1FBEC5830CBQ36299958-0428DC6A-D3CB-44E1-ADBA-45077CE2E9D5Q36356951-4AB642CF-7939-4FC7-ABE1-4C745AA73B13Q36478766-43271A1E-6F77-42D8-8372-A0EFA4B8F6FFQ36620700-A90CE1FF-F847-406F-8FC0-4DC5726F21F3Q36661303-C8C60697-0D80-4284-99C2-33FE1636DCAAQ36743142-34501296-9C23-43E8-A1A7-0DFF8F689DC8Q36826201-2D56F3CD-3CFE-4537-9AE2-1863EDA26277Q36827134-26CCE08E-3E00-4A2D-84AE-AB09A98044A9Q36900195-22454B95-197B-4E96-80B7-FE41C98C04A1Q36986043-1ECCA626-C83D-4CA7-8AAD-F7851698F634Q37027264-1DCF1411-EBD6-4E95-A7DB-5AC5272E6745Q37081486-DB2F68CB-5D6C-458F-A05B-A7F7968F8D5AQ37131025-422A8D46-8A2F-4F8F-A27B-74625FF6C797Q37156636-F61958A0-C9A8-4AA5-91BA-1F300B3C61CAQ37334114-79CC285A-9458-4682-A7C6-DF7ACA9073DEQ37642554-9110AFC6-0A0B-4111-9834-0F7BE48FF8D9Q37664478-CA942131-E2FF-4BAA-884F-C08BE552AE1CQ37669457-24459FBB-7F5C-43D6-9495-942B3F4175F6Q37693964-A12EC076-6BAD-430C-87C7-F68C1BDE9BADQ38912240-E6D62F2F-EF70-4999-889D-0AAEC5A2B142Q43042832-9317E82F-6F84-43BE-AB5B-93784F0E3162Q44350716-E54C3B12-4B64-49AF-86FC-956E558F9BDDQ47260366-B1772027-E2BB-4B80-8B5D-3290FBFCB645
P2860
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
CD4+ T-cell-directed antibody ...... results of a randomized study.
@en
CD4+ T-cell-directed antibody ...... results of a randomized study.
@nl
type
label
CD4+ T-cell-directed antibody ...... results of a randomized study.
@en
CD4+ T-cell-directed antibody ...... results of a randomized study.
@nl
prefLabel
CD4+ T-cell-directed antibody ...... results of a randomized study.
@en
CD4+ T-cell-directed antibody ...... results of a randomized study.
@nl
P2093
P1476
CD4+ T-cell-directed antibody ...... results of a randomized study.
@en
P2093
Akshay K Vaishnaw
Alice B Gottlieb
Bernard Goffe
Ellen Frankel
Hans D Ochs
Janet L Roberts
Ken Washenik
Kenneth B Gordon
Nicholas Lowe
Thomas B Casale
P304
P356
10.1016/S0190-9622(03)01836-X
P407
P577
2003-11-01T00:00:00Z